Kai Yuichiro, Tsutani Yasuhiro, Tsubokawa Norifumi, Ito Masaoki, Mimura Takeshi, Miyata Yoshihiro, Okada Morihito
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8551, Japan.
Oncol Lett. 2019 Mar;17(3):3607-3614. doi: 10.3892/ol.2019.9979. Epub 2019 Jan 28.
The present study analyzed surgical results in patients with malignant pleural mesothelioma (MPM) who underwent extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Data for 44 patients who achieved macroscopic complete resection following neoadjuvant chemotherapy followed by EPP (n=29) or P/D (n=15) were reviewed. Patient demographics and oncological outcomes were compared between the EPP and P/D groups. The median overall (OS) and progression-free survival (PFS) times were 22 and 14 months, respectively. OS was significantly different between the EPP and P/D groups (median OS, 17 vs. 34 months; 5-year OS, 11 vs. 44%; P=0.019); no difference was noted in PFS (median PFS, 13 vs. 21 months; 5-year PFS, 11 vs. 17%; P=0.373). Univariate analysis demonstrated that epithelial histology (P=0.0003) and P/D (P=0.018) were significant favorable prognostic factors for OS. Using multivariate analysis, epithelial histology (P=0.001) remained the only significant factor. Post-recurrence survival (PRS) among all patients was significantly longer in the P/D group (median PRS, 3 vs. 20 months; 1.5-year PRS, 5 vs. 54%; P=0.003), even among patients with epithelial-type MPM (median PRS, 6 s vs. 20 months; 1.5-year PRS, 8 vs. 61%; P=0.012). Chemotherapy following recurrence (P=0.033) was significantly associated with superior PRS in multivariate analysis. Postoperative pulmonary function was significantly improved in the P/D group. In summary, P/D may be an alternative procedure to EPP for resectable MPM providing similar PFS and improved PRS.
本研究分析了接受胸膜外全肺切除术(EPP)或胸膜剥脱术/去皮质术(P/D)的恶性胸膜间皮瘤(MPM)患者的手术结果。回顾了44例在新辅助化疗后接受EPP(n = 29)或P/D(n = 15)并实现宏观完全切除的患者的数据。比较了EPP组和P/D组的患者人口统计学和肿瘤学结局。总生存期(OS)和无进展生存期(PFS)的中位数分别为22个月和14个月。EPP组和P/D组的OS有显著差异(OS中位数,17个月对34个月;5年OS率,11%对44%;P = 0.019);PFS无差异(PFS中位数,13个月对21个月;5年PFS率,11%对17%;P = 0.373)。单因素分析表明,上皮组织学类型(P = 0.0003)和P/D(P = 0.018)是OS的显著有利预后因素。多因素分析显示,上皮组织学类型(P = 0.001)仍然是唯一的显著因素。P/D组所有患者的复发后生存期(PRS)明显更长(PRS中位数,3个月对20个月;1.5年PRS率,5%对54%;P = 0.003),即使是上皮型MPM患者也是如此(PRS中位数,6个月对20个月;1.5年PRS率,8%对61%;P = 0.012)。多因素分析显示,复发后化疗(P = 0.033)与较好的PRS显著相关。P/D组术后肺功能有显著改善。总之,对于可切除的MPM,P/D可能是EPP的替代手术,可提供相似的PFS并改善PRS。